[Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)].
Troglitazone (CAS 97322-87-7), rosiglitazone (CAS 155141-29-0) and pioglitazone (CAS 111025-46-8) represent novel agents for the treatment of diabetes mellitus. Very often such patients receive several drugs at the same time and consequently their interaction potential needs to be known, especially as troglitazone was recently withdrawn from the market partly because it inhibited and induced drug metabolism.